|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:ranitidine
|
|
gptkbp:activities
|
H2 receptor antagonist
|
|
gptkbp:approves
|
gptkb:1986
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Pepcid
|
|
gptkbp:category
|
B
low
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:community_service
|
safe
|
|
gptkbp:contraindication
|
hypersensitivity to famotidine
|
|
gptkbp:dosage_form
|
20 mg to 40 mg
reduced dosage recommended
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
injection
oral tablet
oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
famotidine
|
|
gptkbp:ingredients
|
C8 H10 N4 O2 S
|
|
gptkbp:interacts_with
|
gptkb:itraconazole
gptkb:ketoconazole
gptkb:procainamide
gptkb:warfarin
|
|
gptkbp:is_atype_of
|
A02 B A03
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
treating gastroesophageal reflux disease (GERD)
treating stomach ulcers
preventing heartburn
|
|
gptkbp:lifespan
|
2.5 to 3.5 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Merck_&_Co.
|
|
gptkbp:products
|
gptkb:ranitidine
gptkb:nizatidine
gptkb:cimetidine
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
muscle pain
nausea
diarrhea
insomnia
constipation
dry mouth
skin rash
|
|
gptkbp:storage
|
room temperature
dry place
protected from light
|
|
gptkbp:symptoms
|
confusion
hallucinations
hypotension
bradycardia
|
|
gptkbp:type_of
|
76824-35-6
|
|
gptkbp:weight
|
334.43 g/mol
|